Recursion Pharmaceuticals is trading 5.75% up at $3.92, with no single cause established for the gain. - On October 15, the company announced positive clinical updates, and Sanofi optioned a development candidate, triggering a $10 million milestone payment. - It also priced a $200 million stock offering of 61.54 million shares at $3.25 each. Dilution may weigh on shares, though no source ties the announcements to the intraday move. - Broader conditions were mixed: inflation-driven rate concerns pressured growth shares, while biotech was higher. The gain does not clearly track either signal.